Early staging classifications for Hodgkin's disease merely reflected the natural history of the disease since no effective therapy was available, with Reed describing two stages in 1902 and Longcope and McKalpin seven by 1920. It was not until considerably later that a classification relevant to a potentially curative local therapy began to appear (Craver, 1948) . In 1950 correlation of presentation features from patients treated with radiotherapy over a 20-year period at a single centre led to the evolution of a classification which is the prototype of that recommended for use today. Peters (1950) and subsequently Peters & Middlemiss (1958) (Kaplan et al., 1964) .
The Rye Classification (Rosenberg, 1966) was an improvement on its predecessor in two ways, first by recognising the subdivision of stage III into stages III and IV and secondly by laying down specific guidelines for the investigation of the patient with Hodgkin's disease. Not only did this permit more meaningful comparison of data from different centres but the techniques available by this time in themselves permitted an increased precision with which Hodgkin's disease could be located anatomically. The practical relevance of this was enhanced by the general, but not complete, acceptance of the 'orderly spread of Hodgkin's disease' (Rosenberg & Kaplan, 1966 Although bipedal abdominal lymphangiography is an accurate diagnostic tool for the assessment of paraortic and paracaval nodal disease, the technique is poor in evaluating lymph nodes in the upper abdomen. Coeliac axis nodes are hardly ever visualised and this is a common site for Hodg-kin's disease to be found at staging laparotomy. Portal, splenic, hilar and mesenteric nodes are never visualised. Other difficulties include the risk of local infection and breathlessness associated with lipid microemboli in patients with large mediastinal masses or extensive retroperitoneal lymph node involvement. The technique may not be possible in patients with peripheral oedema. Computed tomography of the abdomen is helpful in evaluating upper abdominal nodal disease and can detect enlargement of coeliac portal and splenic hilar nodes. CT scanning is capable of demonstrating additional mediastinal adenopathy not detected on plain radiographs and may show extension into extra nodal tissues such as lung, pericardium and chest wall. This information can be important in planning radiotherapy treatment fields and deciding whether chemotherapy should be used. For these reasons CT scanning of the chest, abdomen and pelvis is recommended and has become routine in the initial evaluation of Hodgkin's disease (Crowther et al., 1979) . Bipedal lymphangiography is being used less often, however the techniques are complementary and ideally both should be used to evaluate the patient fully (Castellino et al., 1984) .
The recommended pretreatment evaluation procedures in the Cotswolds report include a number of parameters which although not directly related to staging are nevertheless of importance in terms of prognosis and may be taken into consideration when planning treatment. These include features not included in the Ann Arbor report such as performance status, age, gender, assessment of mediastinal bulk (defined as the maximum width equal or greater than one third of the internal transverse diameter of the thorax at the level of T5/6) and measurements of serum lactate dehydrogenase and albumin. Measurements of ESR, total lymphocyte count and number of nodal sites of involvement are also of prognostic importance and are recommended in the initial evaluation.
An additional problem covered by the Cotswolds report included the definition of complete remission following the recognition that residual abnormality of radiology, such as abnormal widening of the mediastinum, minor abnormalities of retroperitoneal tissues on CT scanning or architectural distortion of lymphography, may persist for many years and may not reflect active disease (Jochelson et al., 1985; Radford et al., 1988) . A new category, CR(u) (unconfirmed/uncertain), has been defined to denote such patients, in whom remission status is unclear. Patients in this category who have completed all initial therapy are in normal health with no clinical evidence of Hodgkin's disease, but some radiological abnormality not consistent with the effects of therapy persists at the site of previous disease.
The recommended staging criteria, although improved, are still imperfect. Methods for measuring nodal masses are imprecise taking into account the difficulty in deciding whether a nodal mass should be considered as a conglomerate mass or multiple discrete nodes and the question of whether chains of nodes should be measured in the transverse or longitudinal axis. Clinical criteria for liver involvement by Hodgkin's disease still allow considerable uncertainty and the definition of remission status will remain imprecise without pathological confirmation. Nevertheless, the Cotswolds report is to be commended for providing up-to-date guidelines for the initial evaluation of patients with Hodgkin's disease, taking into account both staging and prognostic factors. This provides a standard base for patient selection for clinical trials and inter-centre comparative studies.
